{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:30:11Z","timestamp":1784716211436,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007543","name":"ANSM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.lanepe.2025.101424","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T02:46:00Z","timestamp":1754534760000},"page":"101424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["High-dose use of pregabalin and gabapentin in France: a retrospective, population-based cohort study"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-9673","authenticated-orcid":false,"given":"Thomas","family":"Soeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Uras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-2475","authenticated-orcid":false,"given":"\u00c9milie","family":"Jouanjus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7172-7835","authenticated-orcid":false,"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lanepe.2025.101424_bib1","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/s41467-023-40637-8","article-title":"Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study","volume":"14","author":"Chan","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101424_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101424_bib3","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/j.pain.2013.05.053","article-title":"Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations","volume":"154","author":"Smith","year":"2013","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101424_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and Gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101424_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and Gabapentin: a systematic review update","volume":"81","author":"Evoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.lanepe.2025.101424_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.639780","article-title":"Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance","volume":"12","author":"Tambon","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.lanepe.2025.101424_bib7","article-title":"Overdose deaths involving non-BZD hypnotic\/sedatives in the USA: trends analyses","volume":"10","author":"Tardelli","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101424_bib8","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/bcp.13892","article-title":"Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France","volume":"85","author":"Driot","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101424_bib10","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-024-01095-y","article-title":"Patterns of pregabalin users from substance abuse treatment facilities: results from the French OPPIDUM program from 2008 to 2022","volume":"38","author":"Garnier","year":"2024","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101424_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neurol.2020.01.361","article-title":"Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations","volume":"176","author":"Moisset","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.lanepe.2025.101424_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2024.104660","article-title":"National impact of a constraining regulatory framework on pregabalin dispensations in France, 2020\u20132022","volume":"135","author":"De Ternay","year":"2025","journal-title":"Int J Drug Policy"},{"issue":"6","key":"10.1016\/j.lanepe.2025.101424_bib14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French national health data system (SNDS) in pharmacoepidemiology: a systematic review in its maturation phase","volume":"79","author":"Maillard","year":"2024","journal-title":"Therapies"},{"key":"10.1016\/j.lanepe.2025.101424_bib15","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev D\u00e9pid\u00e9miol Sant\u00e9 Publ"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101424_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101424_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/pds.5683","article-title":"Core concepts in pharmacoepidemiology: measurement of medication exposure in routinely collected healthcare data for causal inference studies in pharmacoepidemiology","volume":"33","author":"Thai","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101424_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997 \u2013 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"issue":"9","key":"10.1016\/j.lanepe.2025.101424_bib19","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","article-title":"The economic burden of disease in France from the national health insurance perspective: the healthcare expenditures and conditions mapping used to prepare the French social security funding act and the public health act","volume":"60","author":"Rachas","year":"2022","journal-title":"Med Care"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101424_bib20","first-page":"3","article-title":"STL: a seasonal-trend decomposition procedure based on loess","volume":"6","author":"Cleveland","year":"1990","journal-title":"J Off Stat"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101424_bib21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"408","key":"10.1016\/j.lanepe.2025.101424_bib22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"9596","key":"10.1016\/j.lanepe.2025.101424_bib24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2025.101424_bib25","series-title":"R: a language and environment for statistical computing [Internet]","year":"2024"},{"key":"10.1016\/j.lanepe.2025.101424_bib26","series-title":"Statistics for biology and health","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","article-title":"Modeling survival data: extending the cox model","author":"Therneau","year":"2000"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101424_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021535","article-title":"Prescribing practice of pregabalin\/gabapentin in pain therapy: an evaluation of German claim data","volume":"9","author":"Viniol","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101424_bib28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14740338.2023.2193397","article-title":"Non-opioid antinociceptive drugs : risk of respiratory depression and death related to concomitant use of gabapentinoids in addition to opioids","volume":"22","author":"Tambon","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.lanepe.2025.101424_bib29","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/add.16261","article-title":"Systematic assessment of non-medical use of prescription drugs using doctor-shopping indicators: a nation-wide, repeated cross-sectional study","volume":"118","author":"Soeiro","year":"2023","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101424_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00228-013-1594-5","article-title":"Factors associated with pregabalin dispensing at higher than the approved maximum dose","volume":"70","author":"Bod\u00e9n","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.lanepe.2025.101424_bib31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0042-101868","article-title":"Use of pregabalin \u2013 a nationwide pharmacoepidemiological drug utilization study with focus on abuse potential","volume":"49","author":"Schjerning","year":"2016","journal-title":"Pharmacopsychiatry"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101424_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40261-017-0530-3","article-title":"Prevalence of gabapentin abuse: Comparison with agents with known abuse potential in a commercially insured US population","volume":"37","author":"Peckham","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"11","key":"10.1016\/j.lanepe.2025.101424_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276867","article-title":"Opioid and gabapentinoid prescriptions in England from 2015 to 2020","volume":"17","author":"Xia","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2025.101424_bib34","article-title":"Trends in gabapentinoid prescribing in UK primary care using the clinical practice research datalink: an observational study","volume":"27","author":"Ashworth","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"8","key":"10.1016\/j.lanepe.2025.101424_bib35","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/pds.5628","article-title":"Rescheduling gabapentinoids had negligible effects on prescribing behaviour by general practitioners in England","volume":"32","author":"Kamerman","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101424_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/add.15691","article-title":"Commentary on perry et al.: New means, new measures\u2014without discarding all the previous ones!","volume":"117","author":"Soeiro","year":"2022","journal-title":"Addiction"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225002169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225002169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T21:40:56Z","timestamp":1764711656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776225002169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S2666776225002169"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101424","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-dose use of pregabalin and gabapentin in France: a retrospective, population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101424"}}